Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wöhrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E; POWER 1 and 2 study groups..

Lancet. 2007 Apr 7;369(9568):1169-78. Erratum in: Lancet. 2008 Jan 12;371(9607):116.

PMID:
17416261
2.

Darunavir: a review of its use in the management of HIV infection in adults.

McKeage K, Perry CM, Keam SJ.

Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007. Review.

PMID:
19323590
3.

Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.

Boffito M, Miralles D, Hill A.

HIV Clin Trials. 2008 Nov-Dec;9(6):418-27. doi: 10.1310/hct0906-418. Review. Erratum in: HIV Clin Trials. 2009 Mar-Apr;10(2):vi. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
19203907
4.

Darunavir: in the treatment of HIV-1 infection.

Fenton C, Perry CM.

Drugs. 2007;67(18):2791-801. Review.

PMID:
18062724
5.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
6.

[Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].

Arazo Garcés P, Omiste Sanvicente T.

Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 10:23-31. Review. Spanish.

PMID:
19195456
7.

Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.

Robertson J, Feinberg J.

Expert Opin Pharmacother. 2012 Jun;13(9):1363-75. doi: 10.1517/14656566.2012.681776. Review.

PMID:
22594781
8.

Darunavir: in treatment-experienced pediatric patients with HIV-1 infection.

McKeage K, Scott LJ.

Paediatr Drugs. 2010 Apr 1;12(2):123-31. doi: 10.2165/11204530-000000000-00000. Review.

PMID:
20218748
9.

A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.

Mauskopf J, Annemans L, Hill AM, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:1-16. doi: 10.2165/11587410-000000000-00000. Review.

PMID:
21182340
10.

Darunavir: an effective protease inhibitor for HIV-infected patients.

Phung BC, Yeni P.

Expert Rev Anti Infect Ther. 2011 Jun;9(6):631-43. doi: 10.1586/eri.11.48. Review.

PMID:
21692667
11.

[Safety and tolerability of darunavir].

Antela López A.

Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 10:32-6. Review. Spanish.

PMID:
19195457
12.

Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.

Lefebvre E, Schiffer CA.

AIDS Rev. 2008 Jul-Sep;10(3):131-42. Review.

13.

Darunavir: a review of its use in the management of HIV-1 infection.

Deeks ED.

Drugs. 2014 Jan;74(1):99-125. doi: 10.1007/s40265-013-0159-3. Review.

PMID:
24338166
14.

Darunavir/cobicistat once daily for the treatment of HIV.

Kakuda TN, Crauwels H, Opsomer M, Tomaka F, van de Casteele T, Vanveggel S, Iterbeke K, de Smedt G.

Expert Rev Anti Infect Ther. 2015 Jun;13(6):691-704. doi: 10.1586/14787210.2015.1033400. Review.

PMID:
25962100
15.

[Darunavir in HIV/HVC/HVB coinfection].

Rivero A, Camacho A, Pérez-Camacho I, Torre-Cisneros J.

Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 10:37-42. Review. Spanish.

PMID:
19195458
16.

A case of possible darunavir/ritonavir-induced peripheral neuropathy: case description and review of the literature.

Lorber M.

J Int Assoc Provid AIDS Care. 2013 May-Jun;12(3):162-5. doi: 10.1177/2325957412471993. Review.

PMID:
23475910
17.

Darunavir: A Review in Pediatric HIV-1 Infection.

Keating GM.

Paediatr Drugs. 2015 Oct;17(5):411-21. doi: 10.1007/s40272-015-0146-0. Review.

PMID:
26323490
18.

Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women.

Khoo S, Peytavin G, Burger D, Hill A, Brown K, Moecklinghoff C, La Porte C, Hadacek MB.

AIDS Rev. 2017 Jan-Mar;19(1):16-23. Review.

PMID:
28182610
19.

Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance.

Capetti A, Cossu MV, Rizzardini G.

Expert Opin Pharmacother. 2015;16(17):2689-702. doi: 10.1517/14656566.2015.1109632. Review.

PMID:
26612518
20.

Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat.

Curran A, Pérez-Valero I, Moltó J.

AIDS Rev. 2015 Apr-Jun;17(2):114-20. Review.

PMID:
26035169

Supplemental Content

Support Center